Last reviewed · How we verify
NCT03854617
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer
Phase 2 trial testing Oral NVB Metronomic in Human Epidermal Growth Factor 2 Negative Carcinoma of Breast in 172 participants. Status unknown.
20 December 2021
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 172 |
| Start date | 20 February 2019 |
| Primary completion | 20 December 2021 |
| Estimated completion | 20 December 2025 |
Drugs / interventions tested
- Oral NVB Metronomic — full drug profile →
- Oral NVB Weekly — full drug profile →
Conditions studied
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast — all drugs for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
Adults 18 to 85, female only, with Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, open-label, parallel, multi-center study, aims to evaluate the efficacy and safety of metronomic chemotherapy with oral Navelbine versus intermittent oral Navelbine in female patients with HER2 negative Metastasis Breast Cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03854617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Currently open trials in the same condition.
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT06348134 — Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surge · Phase 2 · recruiting
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03854617 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 26 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03854617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing